Patents by Inventor Ronald W. Ratcliffe

Ronald W. Ratcliffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7432284
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Pagets disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: October 7, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Dann LeRoy Parker, Robert R. Wilkening, Dongfang Meng, Ronald W. Ratcliffe
  • Patent number: 7157604
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: January 2, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Dongfang Meng, Dann LeRoy Parker, Jr., Robert R. Wilkening, Ronald W. Ratcliffe
  • Patent number: 7087599
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
    Type: Grant
    Filed: February 14, 2001
    Date of Patent: August 8, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Dann LeRoy Parker, Jr., Ronald W. Ratcliffe, Robert R. Wilkening, Kenneth J. Wildonger
  • Publication number: 20040127576
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant inventive are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynecomastia, autoimmune disease, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer of the lung, colon, breast, uterus, and prrostate.
    Type: Application
    Filed: January 20, 2004
    Publication date: July 1, 2004
    Inventors: Konrad Koehler, Cecilia Hensen, Marita Nilsson, Mikael Gillner, Ye Liu, Andrei Sanin, Robert R. Wilkening, Ronald W. Ratcliffe, David Wensbo
  • Publication number: 20030027840
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
    Type: Application
    Filed: February 14, 2001
    Publication date: February 6, 2003
    Inventors: Dann LeRoy Parker, Ronald W. Ratcliffe, Robert R. Wilkening, Kenneth J. Wildonger
  • Patent number: 6399597
    Abstract: Compounds of formula I are disclosed. as well as pharmaceutically acceptable salts thereof. The naphthosultam is substituted with various substituent groups including at least one cationic group —A—Q—L—B. The carbapenems of the invention are effective against susceptible bacterial organisms, including methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant Staphylococcus epidermidis (MRSE), and methicillin resistant coagulase negative Staphylococci (MRCNS).
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: June 4, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Lovji D. Cama, Ronald W. Ratcliffe, Robert R. Wilkening, Kenneth J. Wildonger, Wanying Sun
  • Patent number: 6346526
    Abstract: Compounds of formula I: as well as pharmaceutically acceptable salts thereof useful as carbapenem antibacterial agents are disclosed wherein X is CH2 or C═O.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: February 12, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Timothy A. Blizzard, Kevin D. Dykstra, Ronald W. Ratcliffe
  • Patent number: 6346525
    Abstract: Compounds of formula I: as well as pharmaceutically acceptable salts thereof and compositions useful as carbapenem antibacterial agents are disclosed.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: February 12, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Timothy A. Blizzard, Ronald W. Ratcliffe, Sherman T. Waddell, Jerry D. Morgan, II
  • Patent number: 6294528
    Abstract: Compounds of formula I: as well as pharmaceutically acceptable salts therefor and compositions useful as carbapenem antibacterial agents are disclosed.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: September 25, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Timothy A. Blizzard, Robert R. Wilkening, Ronald W. Ratcliffe
  • Patent number: 6294529
    Abstract: Compounds of formula I are disclosed. as well as pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: September 25, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Lovji D. Cama, Ronald W. Ratcliffe, Robert R. Wilkening, Kenneth J. Wildonger, Wanying Sun
  • Patent number: 6291448
    Abstract: Compounds of formula I: as well as pharmaceutically acceptable salts thereof useful as carbapenam antibacterial agents are disclosed wherein X is CR2R2, NR2, or O.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: September 18, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Timothy A. Blizzard, Robert R. Wilkening, Ronald W. Ratcliffe
  • Patent number: 6265395
    Abstract: Compounds of formula I: as well as pharmaceutically acceptable salts thereof useful as carbapenem antibacterial agents are disclosed.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: July 24, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Timothy A. Blizzard, Ronald W. Ratcliffe
  • Patent number: 6251890
    Abstract: The present invention relates to carbapenem antibacterial agents of formula I: or a pharmaceutically acceptable salt thereof, wherein: R2 represents: in formula I, in which the carbapenem nucleus is substituted at the 2-position with a naphthosultam linked through a CH2 group. The naphthosultam is further substituted with various substituent groups including at least one cationic group.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: June 26, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Timothy A. Blizzard, Ronald W. Ratcliffe, Jerry D. Morgan, II, Robert R. Wilkening
  • Patent number: 6140318
    Abstract: Compounds of formula I are disclosed. ##STR1## as well as pharmaceutically acceptable salts thereof. The naphthosultam is substituted with various substituent groups including at least one cationic group -A-Q-L-B.The carbapenems of the invention are effective against susceptible bacterial organisms, including methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant Staphylococcus epidermidis (MRSE), and methicillin resistant coagulase negative Staphylococci (MRCNS).
    Type: Grant
    Filed: October 8, 1998
    Date of Patent: October 31, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Lovji D. Cama, Robert R. Wilkening, Ronald W. Ratcliffe, Kenneth J. Wildonger, Wanying Sun
  • Patent number: 6054434
    Abstract: 8a-Azalides are useful in the treatment and prevention of bacterial respiratory and enteric infections in livestock animals, particularly in cattle and swine.
    Type: Grant
    Filed: September 9, 1998
    Date of Patent: April 25, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Helmut Kropp, Daniel O. Farrington, Jeffrey N. Clark, Ronald W. Ratcliffe, Robert D. Wilkening
  • Patent number: 6008212
    Abstract: Compounds of formula I: ##STR1## as well as pharmaceutically acceptable salts thereof are disclosed. R.sup.2 is H and R.sup.3 is C1-3 alkyl, or R.sup.2 and R.sup.3 taken in combination represent C.sub.1-3 alkylidene. Pharmaceutical compositions and methods of treatment are also included. The compounds are useful against methicillin resistant staphylococci (MRSA).
    Type: Grant
    Filed: October 8, 1998
    Date of Patent: December 28, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Ronald W. Ratcliffe, Timothy A. Blizzard
  • Patent number: 5994345
    Abstract: Carbapenems substituted with a naphthosultam at position 2 and linked through a CH.sub.2 group are disclosed. Pharmaceutical compositions and methods of treatment are also included. The naphthosultam is substituted with at least one cationic group --A--Q--L--B. ##STR1## A--Q--L--B represents a side chain wherein in part: A is a C.sub.1-6 alkylene group, straight or branched, and optionally interrupted or terminated by 1-2 of --O--, --S--, NR.sup.a --, --C(O)-- and CH.dbd.CH--Q is ##STR2## L represents a C.sub.1-8 alkylene group, straight or branched, and unsubstituted or substituted with 1-3 R.sup.c groups andB represents ##STR3## The carbapenems of the present invention are useful against gram positive microorganisms, especially methicillin resistant Staphylococci.
    Type: Grant
    Filed: October 8, 1998
    Date of Patent: November 30, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Lovji D. Cama, Robert R. Wilkening, Ronald W. Ratcliffe, Kenneth J. Wildonger, Wanying Sun
  • Patent number: 5985844
    Abstract: Compounds of the formula: ##STR1## where R is hydrogen, hydroxyl, alkyl or acyl, R' and R" together are oxo, hydroxyimino or alkoxyimino, and R' and R" independently are hydrogen, hydroxyl, acyloxy, or amino substituted by any of hydrogen, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylsulfonyl or arylsulfonyl, and n is 0 or 1, and the pharmaceutically acceptable salts thereof. The compounds are macrolide antibiotics and are also useful as intermediates to the synthesis of other macrolide antibiotics. Pharmaceutical compositions and methods of their use are also provided for.
    Type: Grant
    Filed: March 26, 1992
    Date of Patent: November 16, 1999
    Assignee: Merck & Co., Inc.
    Inventors: James V. Heck, William J. Leanza, Ronald W. Ratcliffe, Thomas N. Salzmann, Kothandaraman Shankaran, Michael J. Szymonifka, Robert R. Wilkening
  • Patent number: 5756725
    Abstract: The present invention relates to carbapenem antibacterial agents in which the carbapenem nucleus is substituted at the 2-position with a naphthosultam linked through a CH.sub.2 group. The naphthosultam is further substituted with various substituent groups including at least one cationic group. The compounds are represented by formula I: ##STR1## Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: May 26, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Robert R. Wilkening, Ronald W. Ratcliffe, Timothy A. Blizzard
  • Patent number: 5496816
    Abstract: Carbapenems of the formula: ##STR1## are disclosed as useful antibacterial agents. Pharmaceutical compositions and methods of use are also disclosed.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: March 5, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Timothy A. Blizzard, Ronald W. Ratcliffe, Sherman T. Waddell, Sandra P. Szumiloski, Robert R. Wilkening, Kenneth J. Wildonger